Fibrinolytic Therapy Market, By Drug Type (Alteplase, Reteplase, Tenecteplase, Streptokinase, Anistreplase,Urokinase), By Indication (Acute Ischemic Stroke, Acute Myocardial Infarction, Deep Vein Thrombosis, Pulmonary Embolism, Peripheral Arterial Thrombosis, Other Thrombotic Conditions), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others), By Administration (Intravenous (IV), Intra-arterial (IA)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Patient Age (Adult Patients, Pediatric Patients), By Packaging Type (Vials, Ampoules, Pre-filled Syringes), By Application (Emergency Care, Interventional Cardiology, Thrombosis Treatment, Others), By Dosage Form (Lyophilized Powder for Reconstitution, Solution for Injection), By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
Fibrinolytic therapy is used to dissolve blood clots that cause heart attacks or strokes. It is a lifesaving treatment, but it fails in underlying health problems that can lead to other serious diseases and conditions. Thrombolysis is usually given through an intravenous line. It is used when symptoms of a stroke or heart attack are present and the patient is not responding to other treatments, like anticoagulants and steroid medications. It can be given at home or in a hospital. Tissue plasminogen activator or alteplase is a drug that breaks down fibrin and other substances that create clots in the body that is most commonly used for thrombolysis. The drug tenecteplase is also effective in some patients, and it can also be given by mouth.
Market Dynamic:
The increasing incidences of trauma and road accidents are driving the demand for antifibrinolytic drugs, which in turn is fuelling fibrinolytic therapy market growth. The growing use of these drugs in oral bleeding treatments, mainly for menorrhagia (heavy menstrual flow) is again anticipated to bolster the market growth further. Moreover, rising incidences of severe road accidents and trauma is creating demand for anti-fibrinolytic drugs, thereby propelling the market growth. Furthermore, rising adoption of these drugs for treating hemophilia and other conditions such as platelet dysfunctions, Von Willebrand diseases and haemophilia A and B is further bolstering the market growth.
Also, the global fibrinolytic therapy market is driven by the rising prevalence of cardiovascular diseases, neurological disorders and pulmonary diseases causing blood clots. As per World Health Organization (WHO), cardiovascular diseases accounts for over 17.9 Mn deaths annually. Moreover, growing geriatric population prone to such diseases contributes to the market growth. However, high costs of fibrinolytic drugs, stringent regulations, and risk of bleeding associated with the therapy inhibits the market expansion. The market provides opportunities for development of effective recombinant variants, synthetic analogs, and hybrid molecules with greater specificity, enhanced fibrin specificity and reduced bleeding risks.
However, the high price of these drugs is a key factor that can hinder the market growth.
Key features of the study:
This report provides in-depth analysis of the global fibrinolytic therapy market, and provides market size (US$ Bn ) and compound annual growth rate (CAGR %) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global fibrinolytic therapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Genentech, Inc. (Roche), Bayer AG, Boehringer Ingelheim International GmbH, Pfizer Inc., Bristol Myers Squibb Company, Novartis AG, AstraZeneca PLC, Johnson & Johnson, Daiichi Sankyo Company, Limited, Merck & Co., Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Mallinckrodt Pharmaceuticals, and Mitsubishi Tanabe Pharma Corporation
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global fibrinolytic therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fibrinolytic therapy market
Detailed Segmentation:
Global Fibrinolytic Therapy Market, By Drug Type:
Alteplase
Reteplase
Tenecteplase
Streptokinase
Anistreplase
Urokinase
Global Fibrinolytic Therapy Market, By Indication:
Acute Ischemic Stroke
Acute Myocardial Infarction
Deep Vein Thrombosis
Peripheral Arterial Thrombosis
Other Arterial Thrombosis
Global Fibrinolytic Therapy Market, By End User:
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others
Global Fibrinolytic Therapy Market, By Administration:
Intravenous (IV)
Intra-arterial (IA)
Global Fibrinolytic Therapy Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Fibrinolytic Therapy Market, By Patient Age:
Adult Patients
Pediatric Patients
Global Fibrinolytic Therapy Market, By Packaging Type:
Vials
Ampoules
Pre-filled Syringes
Global Fibrinolytic Therapy Market, By Application:
Emergency Care
Interventional Cardiology
Thrombosis Treatment
Others
Global Fibrinolytic Therapy Market, By Dosage Form:
Lyophilized Powder for Reconstitution
Solution for Injection
Global Fibrinolytic Therapy Market, By Region:
North America
Europe
Asia Pacific
Latin America
Middle East
Africa
Top Companies in the Global Fibrinolytic Market:
Genentech, Inc. (Roche)
Bayer AG
Boehringer Ingelheim International GmbH
Pfizer Inc.
Bristol Myers Squibb Company
Novartis AG
AstraZeneca PLC
Johnson & Johnson
Daiichi Sankyo Company, Limited
Merck & Co., Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Abbott Laboratories
Mallinckrodt Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Type
Market Snippet, By Indication
Market Snippet, By End User
Market Snippet, By Administration
Market Snippet, By Distribution Channel
Market Snippet, By Patient Age
Market Snippet, By Packaging Type
Market Snippet, By Application
Market Snippet, By Dosage Form
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Driver
Increasing incidence of cardiovascular diseases
Growing geriatric population
Technological advancements
Access to healthcare facilities
Restrain
Limited efficacy in certain patient populations
Risk of bleeding complications
Availability of alternative treatment modalities
Time sensitivity and door-to-needle delays
Opportunities
Emerging markets
Combination therapies
Telemedicine and remote treatment
Personalized medicine
Key Highlights
Regulatory Scenario
Recent Trends
Product Launches/Approvals
PEST Analysis
PORTER’s Analysis
Mergers, Acquisitions, and Collaborations
4. Global Fibrinolytic Therapy Market – Impact of Coronavirus (COVID-19) Pandemic
COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact
5. Global Fibrinolytic Therapy Market, By Drug Type, 2018-2030, (US$ Bn)
Introduction
Market Share Analysis, 2018 and 2030 (%)
Y-o-Y Growth Analysis, 2019 – 2030
Segment Trends
Alteplase
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Reteplase
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Tenacteplase
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Streptokinase
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Anistreplase
Introduction
Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Urokinase
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
6. Global Fibrinolytic Therapy Market, By Indication, 2018-2030, (US$ Bn)
Introduction
Market Share Analysis, 2018 and 2030 (%)
Y-o-Y Growth Analysis, 2019 – 2030
Segment Trends
Acute Ischemic Stroke
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Acute Myocardial Infarction
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Deep Vein Thrombosis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Peripheral Arterial Thrombosis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Other Arterial Thrombosis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,US$ Bn(US$ Bn)
7. Global Fibrinolytic Therapy Market, By End User, 2018-2030, (US$ Bn)
Introduction
Market Share Analysis, 2018 and 2030 (%)
Y-o-Y Growth Analysis, 2019 – 2030
Segment Trends
Hospitals
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Ambulatory Surgical Centers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Speciality Clinics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
8. Global Fibrinolytic Therapy Market, By Administration, 2018-2030, (US$ Bn)
Introduction
Market Share Analysis, 2018 and 2030 (%)
Y-o-Y Growth Analysis, 2019 – 2030
Segment Trends
Intravenous (IV)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Intra-arterial (IA)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
9. Global Fibrinolytic Therapy Market, By Distribution Channel, 2018-2030, (US$ Bn)
Introduction
Market Share Analysis, 2018 and 2030 (%)
Y-o-Y Growth Analysis, 2019 – 2030
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
10. Global Fibrinolytic Therapy Market, By Patient Age, 2018-2030, (US$ Bn)
Introduction
Market Share Analysis, 2018 and 2030 (%)
Y-o-Y Growth Analysis, 2019 – 2030
Segment Trends
Adult Patients
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Pediatric Patients
11. Global Fibrinolytic Therapy Market, By Packaging Types, 2018-2030, (US$ Bn)
Introduction
Market Share Analysis, 2018 and 2030 (%)
Y-o-Y Growth Analysis, 2019 – 2030
Segment Trends
Vials
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Ampoules
Pre-filled Syringes
12. Global Fibrinolytic Therapy Market, By Application, 2018-2030, (US$ Bn)
Introduction
Market Share Analysis, 2018 and 2030 (%)
Y-o-Y Growth Analysis, 2019 – 2030
Segment Trends
Emergency Care
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Interventional Cardiology
Thrombosis Treatment
Others
13. Global Fibrinolytic Therapy Market, By Dosage Form, 2018-2030, (US$ Bn)
Introduction
Market Share Analysis, 2018 and 2030 (%)
Y-o-Y Growth Analysis, 2019 – 2030
Segment Trends
Lyophilized Powder for Reconstitution
Solution for Injection
14. Global Fibrinolytic Therapy Market , By Region, 2018-2030, (US$ Bn)
Introduction
Market Share Analysis, By Region, 2018 and 2030 (%)
Y-o-Y Growth Analysis, For Region, 2018 –2030
Country Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Administration, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
GCC Countries
Israel
Rest of Middle East
Africa
South Africa
Central Africa
North Africa
15. Competitive Landscape
Company Profile
Genentech, Inc. (Roche)
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Bayer AG
Boehringer Ingelheim International GmbH
Pfizer Inc.
Bristol Myers Squibb Company
Novarts AG
AstraZeneca PLC
Johnson & Johnson
Daiichi Sankyo Company, Limited
Merck & Co., Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Abbott Laboratories
Mallinckrodt Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation
Analyst Views
16. Section
References
Research Methodology
About us
*Browse 75 market data tables and 60 figures on "Global Fibrinolytic Therapy Market” - Global forecast to 2030